Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084337 | 0.84 | ALOX5 (0.41) | ADORA3POLQMAPTLMNATP53 | |
| SCHEMBL11916730 | 0.82 | F2RL3 (0.50) | F2RL3ADORA3GPR52POLQTRPM8 | |
| SCHEMBL12728512 | 0.81 | ALOX5 (0.46) | F2RL3MAPTCDK2KDM4EMEN1 | |
| SCHEMBL327274 | 0.81 | CDK4 (0.51) | ADORA3GPR52TRPM8MAPTCDK4 | |
| SCHEMBL3976157 | 0.78 | TRPM8 (0.47) | GPR52TRPM8MAPTKDM4EMEN1 | |
| SCHEMBL9955315 | 0.78 | TRPM8 (0.44) | ADORA3GPR52TRPM8MAPTLMNA | |
| SCHEMBL8084192 | 0.78 | MAPT (0.51) | GPR52TRPM8MAPTLMNAKDM4E | |
| SCHEMBL2632548 | 0.76 | CA12 (0.42) | ADORA3GPR52TRPM8MAPTCDK4 | |
| SCHEMBL7948630 | 0.74 | GPR52 (0.39) | ADORA3GPR52TRPM8MAPTKDM4E | |
| SCHEMBL16806021 | 0.73 | TRPM8 (0.51) | ADORA3TRPM8MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | F2RL3 1645/4885PDGFRB 1796/4885PDGFRA 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.